



Elixinol Global to Present at Upcoming U.S. Investor Conferences

SYDNEY, May 13, 2019 – Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is attending the following investor conferences in May and June 2019.

3rd Annual Canaccord Genuity Cannabis Conference

When: Tuesday, May 14, 2019

Where: The Grand Hyatt – New York, NY

Presentation: 1:00 p.m. Eastern time

Webcast: Please click [here](#)

Cowen & Co. Toronto Cannabis Summit

When: Wednesday, May 22, 2019

Where: The Westin Harbour Castle – Toronto, ON

Presentation: 1x1 and small group meetings

39th Annual Piper Jaffray Consumer Marketplace Conference

When: Thursday, June 6, 2019

Where: The Pierre Hotel – New York, NY

Presentation: U.S. CBD Players panel at 9:30 a.m. Eastern time

For more information about the conferences or to schedule a one-on-one meeting with EXL's management, please contact your respective conference representative or the Company's U.S. investor relations team at USIR@elixinolglobal.com.

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL's businesses include:

- Elixinol LLC ("Elixinol"), founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, USA.
- Hemp Foods Australia Pty Ltd ("Hemp Foods Australia"), founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products.
- Nunyara Pharma Pty Ltd ("Nunyara"), formerly known as Elixinol Australia, was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.



See more at www.elixinolglobal.com

U.S. Investor Relations Contact:

Cody Slach
Managing Director, Gateway IR
USIR@elixinolglobal.com
+1 949 574 3860

Australian Investor Relations Contact:

Glen Zurcher
Account Director, IR Department
IR@elixinolglobal.com
+61 420 249 299

Media Contact:

Chris Husong
Elixinol
chris@elixinol.com
+1 844-804-3504 ext. 420



Elixinol Global Limited

Investor update, May 2019



Disclaimer

This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

The information contained in this presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek independent professional advice appropriate to their jurisdiction and circumstances.

To the maximum extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by EXL, any of its related bodies corporate or its directors, officers, employees, professional advisers and agents (Related Parties). No representation or warranty, express or implied, is made by any person, including EXL and its Related Parties, as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

An investment in EXL securities is subject to investment and other known and unknown risks, some of which are beyond the control of EXL or its directors. EXL does not guarantee any particular rate of return or the performance of EXL securities.

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of EXL and associated entities of EXL and certain plans and objectives of the management of EXL. Forward-looking statements can be identified by the use of forward-looking terminology, including, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may" or "will", and similar expressions. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of EXL to be materially different from the results or performance expressed or implied by such forward-looking statements.

Such forward-looking statements are based on numerous assumptions regarding EXL's present and future business strategies and the political, regulatory and economic environment in which EXL will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved. Forward-looking statements speak only as at the date of this presentation and to the maximum extent permitted by law, EXL and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, any assumptions or expectations set out in this presentation).

All figures in this presentation are A\$ unless stated otherwise and all market shares are estimates only. A number of figures, amounts, percentages, estimates, calculations of value and fractions are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this presentation.

| Agenda

Cannabis definition	4
Who we are	5
Key highlights for FY2018 / Q1 FY2019	9
Business overview	11
Financial results FY2018	21
Outlook	25
Appendix	28

HEMP



MARIJUANA

Plant names

Hemp, industrial hemp, hemp food, hemp fibre, hemp stalk

Appearance and growing conditions

Tall, woody plant.

Intoxicating properties

No intoxicating properties.
Less than 1% THC.
Will not cause you to fail a drug test.



Uses

Over 50,000 different uses.
Foods, Skincare, Natural fibre
e.g. paper, clothing, rope.



Plant names

Medical cannabis, recreational cannabis marijuana

Appearance and growing conditions

Short, wide, bushy shrub.

Intoxicating properties

Contains intoxication properties.
Contains up to 30% THC.
100 times more than what is found in hemp.



Uses

Grown specifically for recreational and medical purpose.



For the first 150 years of Australia's European settlement, Hemp was legal as a food and Marijuana was legal for medical and recreational use. The stance on this changed in the late 1930's, when both were made illegal due to fear and confusion about their use. Now, they are back in the spotlight and are being recognised for their nutritional and medical benefits.

Who we are

www.elixinolglobal.com

Who we are

Benefiting health and wellness in communities around the world

Elixinol Global (herein referred to as EXL) is a global consumer brand with products in multiple cannabis verticals, including CBD-based supplements and skincare, hemp food and medical cannabis.

- Committed to providing the **highest quality products** through proprietary water soluble and bio-available technology and extraction methods.
- Elixinol* based in Colorado, widely recognized as a **top CBD company globally** with distribution to North America, Asia Pacific and Europe and growing hemp foods business
- Hemp Foods Australia is a leading Australian brand of hemp foods
- Combined, Elixinol and Hemp Foods Australia have ~ 90 SKUs**
- Management team brings more than two decades of hemp/cannabis experience
- EXL reported **record revenue** achieved in FY2018 of \$37.1m and underlying EBITDA of \$0.7m
- **Strong net cash position** of \$27.4m (31 March 2019) to accelerate growth and capitalize on the growing global demand for hemp and cannabis-derived products.

* Elixinol is a supplier of bulk CBD to the Pet Releaf (incl. Edibites) range of products as well as providing private label finished goods production services and is also a distributor of Pet Releaf products

** Stock Keeping Units (SKUs)



Why we're different

We believe our products represent the highest quality in the market

- **Widely recognized global brand** with industry leading products, delivered in multiple forms
- **Highly diversified business model** with multiple products sold through multiple sales channels
- **In-house R&D efforts** focused on developing new technologies, formulations and delivery systems to maximize bioavailability of our products
- **24 years of experience** in the industry by our Founder and CEO, Paul Benhaim
- Hubs located in the U.S., Australia and Japan with distribution in North America, Asia Pacific and Europe
- **Vertical integration** enables us to actively manage our supply, distribution, pricing and margins



CREATE | BUILD | DREAM
RAPIDLY DISSOLVING CBD POWDER



Corporate overview

Board and management team



Andrew Duff | Non-Executive Chairman

Experienced ASX listed company director. Ex CFO of ASX100 company, Primary Healthcare (ASX: PRY), current Chairman of Cornerstone Health.



Paul Benhaim | CEO / Executive Director

Over 25 years' experience in the hemp industry and is the co-founder of Elixinol USA, Nunyara and Hemp Foods Australia.



Linda McLeod | Managing Director

Over 30 years in business advisory, corporate finance, private equity and venture capital. Exec in Hemp Foods Australia and Nunyara Pharma.



Greg Ellery | Non-Executive Director

Global CPG specialist with experience in prior CEO and executive roles with Asahi Premium Beverages, Spectrum Brands, Polaroid Corp, Fosters Group and New Balance.



Ron Dufficy | CFO and Company Secretary

Senior finance executive with significant experience growing highly regulated businesses in global markets. Formerly with Aristocrat (ASX: ALL) and CSR Ltd (ASX: CSR).



Stratos Karousos | Chief Commercial and Legal Officer³

Commercial lawyer with extensive experience in top tier law firms (Baker McKenzie and Clayton Utz); cross-sector experience in M&A, ECM, corporate restructuring, PE transactions, JVs, & corporate governance.



Gabriel Ettenson | President of Elixinol USA

Co-founder and head of Elixinol USA team. Active member of several hemp lobbying groups.

Substantial holders

Raw With Life Pty Ltd (as trustee for Benhaim Trading Trust)	43.86%
D&G Health LLC	10.21%

Key market statistics¹

ASX: EXL

OTCQX: ELLXF

Share price (9 May 2019) A\$4.89

Market capitalization (9 May 2019) A\$612m

Shares on issue² 125.13m
Of which 77.87m escrowed shares until 8 January 2020

Cash balance (31 March 2019) A\$27.4m

Key market statistics



¹ EXL reports in A\$ million and 31 December year end.

² As at 24 April 2019, last reported Appendix 3B.

³ Role effective post 24 May 2018. Currently Non-Executive Director, Elixinol Global, up to and including 23 May 2019.

A decorative graphic on the left side of the slide features several overlapping, white, petal-like shapes with soft shadows, set against a solid blue background that forms a horizontal band across the middle of the slide.

Key highlights

www.elixinolglobal.com

Key highlights for FY2018 & Q1 FY2019 (December 31 year end)

1 Group Results FY2018

Revenue	FY2018 \$37.1m vs FY2017 \$16.8m, 121% growth
Underlying EBITDA	FY2018 \$0.7m vs FY2017 breakeven
Underlying NPAT	FY2018 \$0.7m vs FY2017 (\$0.6)m loss

Strong revenue growth; scaling the business for expected future growth

2 Strong segment performance from USA FY2018

Revenue	FY2018 \$32.5m vs FY2017 \$13.5m, 141% growth
Gross profit margin	FY2018 57% vs FY2017 67% driven by growth in lower margin private label products
EBITDA	FY2018 \$4.6m vs FY2017 \$2.5m, 84% growth

Investing for expected future revenue growth

EBITDA margin	FY2018 14% vs FY2017 18%
----------------------	--------------------------

3 Key Milestones FY2018 & Q1 FY2019

- Large US national retail distribution commenced (April 2019)**
National US retail distribution commenced and in-store. UK high street retailer confirmed for launch in June. Agreement signed with Presence Marketing (a leading national brokerage firm with access to over 15,000 retail stores) to drive future sales
- Expansion of Elixinol production facility in Colorado (on track to be commissioned H1 FY2019)**
Expanding US facilities to ~20,700 sq. ft. to increase production capacity to facilitate expected growth (5,000kg of ethanol-extracted hemp CBD and 3,125kg of CO2-extracted hemp CBD (will enable production of 24,000 bottles per day)
- Board and executive strengthened (April 2019)**
Greg Ellery, retail and consumer specialist, appointed to the board as Non-Executive Director
Stratos Karousos appointed as Chief Commercial and Legal Officer**
- Strategic investment made into leading US CBD pet supplier, Pet Releaf; 25% ownership (April 2019); Japanese distribution company, 50.5% ownership (November 2018) and Northern Colorado High Plains Producers (NCHPP) joint venture (April 2018) - to supply and produce high-cannabidiol (CBD) hemp**
- Favorable legislative changes: US Farm Bill (December 2018)**
2018 Farm Bill enacted in December and expected to significantly open up trade and marketing opportunities to the hemp-derived CBD industry. New Zealand legislation change (allowing hemp CBD (low THC) prescriptions).
- Strong balance sheet with \$27.4m net cash (per 31 March 2019) working capital to facilitate EXL's global international growth**
Focused on building sales and marketing and production capacity, and establish Nunyara

* FY2017 is shown on a pro forma basis. EXL reports in A\$million and 31 December year end.

** Role effective post 24 May 2018. Currently Non-Executive Director, Elixinol Global, up to and including 23 May 2019.

A decorative graphic on the left side of the slide features several overlapping white, stylized leaves or petals. These shapes are layered over a solid blue horizontal band that spans the width of the slide. The leaves have soft shadows, giving them a three-dimensional appearance.

Business overview

www.elixinolglobal.com

Diversified portfolio

FY2018 revenue by business unit



Consumer Products

Dietary Supplements



Revenue \$32.5m (87%)*



45 products**:

- Tinctures
- Capsules
- Liposomes
- Hemp oil
- Topical products
- SATVA Skincare

Hemp Foods



Revenue \$4.9m (13%)*



43 products**:

- Hemp seeds
- Hemp flour
- Hemp protein
- Hemp oil
- SATVA Skincare

Pharmaceutical

Medical Cannabis



Seeking license and permit

Submitted license applications for cultivation and manufacture to Office of Drug Control (ODC) in H1 FY2018

Name change to Nunyara Pharma Pty Ltd "Nunyara" from Elixinol Pty Ltd in late 2018

Unique 60-acre land holding purchased in February 2019 in Australia

Strong growth trajectory across key metrics

EXL has maintained a strong growth trajectory

Revenue

A\$ million, 31 December year end




Comments

- Organic revenue growth of 121%
- Underpinned by strong growth in Elixinol's hemp derived CBD products
- Favorable legislative changes (US Farm Bill and New Zealand) have provided enhanced business and product profile for future growth

* FY2017 shown on a pro forma basis

Underlying EBITDA

A\$ million, 31 December year end



Comments


- Investing for top line revenue growth and production efficiencies across all businesses
- Investing for:
 - Continuing R&D into bio-available and water soluble bio-technologies
 - Securing supply for growing demand
 - Implementing Enterprise Resourcing Planning systems
 - Manufacturing capacity
 - Distribution
 - Investment into marketing
 - Growing world-class team
 - E-commerce

Revenue growth by Consumer Products segment, FY2018

Growth across all revenue segments with a clear strategy to drive higher margin products

Elixinol USA

A\$ million, 31 December year end




Comments

- Continued focus on direct to consumer sales of branded products which are higher margin
- Strong future growth expected from wholesale sales
- Production efficiencies expected as the business continues to scale
- Strategic decision in Q1 FY2019 to reduce focus on low margin private label business in the US moving forward

Hemp Foods Australia

A\$ million, 31 December year end




Comments

- Strong growth in bulk sales driven by favorable regulatory change to legalize hemp in Australia for human consumption
- Investment in sales and marketing teams with focus on new branded product sales through national distribution

Quarterly revenue growth

A\$ million, 31 March 2019, PCP



- Modest Q1 FY2019 (January to March) growth reported across both wholesale and bulk sales in the US
- Revenue reflects the strategic decision to reduce focus on low margin private label business in the US moving forward
- Decision will enable increased capacity for expected future growth of higher margin branded products and provide the ability to capture further market share
- First large retailer distribution agreements signed in US and Europe (Cambrian Alliance Group - UK) in April 2019
- Impact of favorable legislative changes (US Farm Bill and New Zealand) to show gradual impact over coming quarters, particularly via potential signing of further large retailer distribution agreements
- Presence Marketing (a leading national brokerage firm with access to over 15,000 retail stores) appointed to support sales into US retailers

Elixinol Global key growth initiatives

Continued disciplined approach to drive future revenue growth

Elixinol
hemp-derived CBD dietary supplements

- ✓ Increase distribution through US national retail chains (commenced April 2019)
- ✓ Expansion of operations in Europe and Japan (first large EU distribution agreement April 2019)
- ✓ Investment in farming and production capabilities to facilitate future growth (new production facility on track for commissioning H1 2019)
- ✓ Key sales hires focused on retail distribution of branded products which is higher margin
- ✓ Improved e-commerce platform and investment in marketing (Presence Marketing – US, appointed in April 2019)
- ✓ Continued focus on core product development, new product launches & building brand strength
- ✓ Ongoing investment in brand quality, US Hemp Authority Certification (received 2019)

Hemp Foods Australia
hemp-derived foods

- ✓ Key sales hires to target core products and new product launches
- ✓ New product development in process with first products launched in early 2019 (Consumer Packaged Goods – Hemp Burgers) with a focus on mainstream FMCG channels
- ✓ SATIVA skincare products launched via health stores and online channels


Nunyara
medical cannabis

- ✓ Progressing license applications with the ODC
- ✓ Advanced plans prepared for build-out of integrated cultivation and manufacture facility program for proprietary products (unique land holding purchased February 2019)
- ✓ Finalizing the development of medical education program for proprietary products

Elixinol Global, international footprint

An established platform that can be leveraged for consumer products

Global platform for growth



- Avenues to market established across North America, Asia Pacific and Europe with mix of direct sales and via distribution partners
- Operations (pins) in:
 - Sydney and Bangalow, Australia
 - Colorado and California, USA
 - Tokyo, Japan
 - Netherlands, UK and Spain
- Expansion plans underway, supported by marketing strategies in:
 - Japan
 - New Zealand
 - Brazil

Growth Drivers: Elixinol

Firmly positioned to drive revenue growth and take CBD market share

- Doubling production capacity in the USA with new 12,000 sq. ft. square foot Colorado facility (on track for commissioning in H1 FY2019); plans to add adjacent ~23,000 sq. ft. facility (secured raw material to facilitate more than intended growth)
- New product development underway, including skincare and pet health-related products (balm and Physician recommended products launched early 2019)
- Key sales hires to focus on optimizing and expanding retail distribution partnerships
- Scaling direct-to-consumer e-commerce platform alongside innovative advertising campaigns, including utilization of “influencers” in sports, lifestyle and well-being segments
- Continued focus on core product development, new product launches and building brand strength
- Europe sales and marketing team including product fulfilment capability established, and US broking partner Presence Marketing appointed (reach into 15,000+ retail stores)
- First large retail distribution agreements signed in US and Europe in April 2019, further agreements expected in FY2019
- Strategic investment made into leading US CBD pet supplier, Pet Releaf; 25% ownership*



Growth Drivers: Hemp Foods Australia

Leveraging industry leading position in Australia to further accelerate growth

- Solidify #1 market position in Australia for hemp food branded products with expanded FMCG distribution channels and optimization of current distribution agreements
- Now marketing selected Hemp Foods Australia products in USA and Europe
- Launched new SATIVA skincare products in 2018 with new packaging and branding in 2019 with most sales via Elixinol
- Implementing several new marketing initiatives, including expansion of brand ambassadors and influencers
- Focus on national distribution for new branded products with a focus on mainstream FMCG channels (Consumer Packaged Goods – Hemp Burgers, launched early 2019)



Growth Drivers: Nunyara Pharma (Australia)

Leveraging US cannabinoid production and formulation expertise for Medical Cannabis

Subject to ODC licenses and planning approvals:

- The planned facility will be 5000m² on a secured 5 acres, within the 60 acre property acquired February 2019)
- State-of-the-art, fully integrated greenhouse cultivation, GMP extraction and manufacturing facility, sustainable and environmentally friendly
- Anticipate production of 1-2 ton of medical cannabis in year one of permitting with capacity to easily expand the proposed GMP certified, Organically grown, pharmaceutical grade facility
- Inbuilt scalability and significant land holding for expansion
- Construction planned for 2019-2020 and production and sales expected late 2020
- Export market opportunities, with proximity to APAC countries providing advantage
- Ability to leverage Elixinol's expertise in processing and manufacture of cannabis products



The background features a large, stylized graphic of white, overlapping petals or leaves on the left side, set against a white background. A solid blue horizontal band spans the width of the slide, positioned below the graphic. The text 'FY2018 financial results' is centered within this blue band.

FY2018 financial results

www.elixinolglobal.com

Financial summary

Building scale to support expected future growth

(\$m)	FY2018	FY2017
Revenue	37.1	16.8
Cost of goods sold	(17.2)	(6.3)
Gross profit	20.0	10.5
<i>Gross profit margin</i>	54%	62%
Other income	0.3	0.4
Operating expenses	(20.4)	(10.9)
Statutory EBITDA	(0.1)	0.0
Underlying EBITDA	0.7	0.0
Interest income	0.4	-
Depreciation and amortization	(0.8)	(0.7)
Profit before tax	(0.5)	(0.7)
Tax expense	(0.4)	(0.6)
Statutory NPAT	(0.9)	(1.3)
Underlying NPAT	0.7	(0.6)

Commentary

Revenue

- growth across all revenue segments has enabled EXL 121% revenue growth vs PCP
- dietary supplements (87% of FY2018 revenue)
- hemp foods (13% of FY2018 revenue)

Cost of goods sold

- variable input costs of raw material, production and packaging

Gross profit

- impacted by strong growth in volumes from lower margin private label sales

Operating expenses

- increased Group costs to expand business operations and facilitate expected future growth
 - sales and marketing costs
FY2018 \$7.4m vs FY2017 \$2.9m (up 155%)
 - employee expenses
FY2018 \$7.1m vs FY2017 \$3.2m (up 122%)
 - Group headcount
Dec 2018 89 vs Dec 2017 43 (up 107%)
- includes ramp up costs for Nunyara (\$0.4m) and Europe (\$0.5m)

Underlying EBITDA

- continue to build scale to support expected future revenue growth

* FY2017 is shown on a pro forma basis. EXL reports in A\$ million and on a 31 December year end.

Cash flow

Re-investment to facilitate expected future growth

(\$m)	FY2018	FY2017
Operating activities	(5.7)	(1.2)
Investing activities	(8.5)	(0.5)
Financing activities	37.7	16.3
Effect of movement in forex	0.6	
Net increase in cash	24.1	
Opening cash on hand	18.8	
Closing cash on hand	42.9	

Commentary

Operating cash flow

- working capital expenditure to facilitate expected future growth
- deposits to secure raw material for FY2019 harvest
- income taxes paid on US profits

Investing cash flow

- \$1.5m investment in NCHPP JV; \$2.2m Elixinol Japan
- \$3.1m investment in production equipment that will provide a significant increase in scale and efficiencies
- \$0.5m Colorado land purchase for future growth
- \$0.6m investment in ecommerce & IT development
- \$0.6m increase in other PPE capex: delivery vehicle, office furniture and computer equipment

Financing cash flow

- September 2018 equity raising \$40.0m
- no debt transactions during the period

* FY2017 is shown on a pro forma basis. EXL reports in A\$ million and on a 31 December year end.

Strong financial position

Strong cash position and minimal debt

(\$m)	31 Dec 2018	31 Dec 2017
Current assets		
Cash and cash equivalents	42.9	18.8
Trade & other receivables	3.5	1.2
Inventories	7.0	2.5
Other	3.6	0.8
Total current assets	57.0	23.3
Non-current assets		
Property, plant and equipment	6.0	1.1
Investments	4.4	-
Intangible assets	80.4	80.6
Other	0.7	0.1
Total non-current assets	91.4	81.8
Total assets	148.4	105.1
Liabilities		
Trade and other payables	6.5	1.3
Other current liabilities	0.6	1.2
Deferred tax liability	3.2	3.2
Other non-current liabilities	0.3	0.3
Total liabilities	10.6	6.0
Total equity	137.8	99.1

* FY2017 is shown on a pro forma basis. EXL reports in A\$ million and on a 31 December year end.

Commentary

Strong cash position

- strong net cash position of \$42.7m to support growth (\$42.9m cash and \$0.25m debt)

Increased working capital to support ongoing growth


- increase in inventories to support ongoing growth
- hemp supply prepayments to support 200%+ production in 2019

Investment for expected future growth

- investment in production capacity to significantly increase the scale of operations
- investments refers to book value of strategic investments in NCHPP JV (\$1.9m) and Elixinol Japan (\$2.5m)

Liabilities

- trade and other payables increased to support inventory purchases and includes \$0.9m NCHPP investment instalment (paid in Q1 FY2019)

A decorative graphic on the left side of the slide features several overlapping white, stylized leaves or petals. These shapes are layered, with some appearing to be behind others, creating a sense of depth. The background is a solid blue horizontal band that spans the width of the slide, with the white shapes partially overlapping it from the left. The overall aesthetic is clean and modern.

Outlook

www.elixinolglobal.com

Outlook

EXL's global investment into top line growth is on track. There is a significant opportunity to grow sales in the US via large national retailers, with ongoing conversations expected to lead to new sales distribution over the coming quarters. USA, Europe and Japan continue to be our focus geographic areas.

Paul Benhaim, CEO Elixinol Global commented:


“ The **positive movement in legislation across industrial hemp markets**, in combination with our own investment into top line growth during the March quarter, underpins EXL's objective of becoming a global leader of CBD consumer products. We have continued to diversify our business across a variety of channels and made significant investments into a number of key geographies globally, including strong headway in Europe. We remain very confident in our future growth strategy as we continue to diversify our branded product mix with a focus on national retail sales.


In the US, we are experiencing **strong interest from national retailers to stock our products** on the back of growing consumer demand. We are very excited to receive our first order from one of the largest national retailers in the US. In the UK, significant retail agreements were signed during the quarter, which will see our CBD products advertised on TV and stocked on shelves in major retail stores and pharmacies in the coming months. We see similar opportunities across many of the global markets that we are currently operating in, with ongoing discussions expected to lead to further agreements over the coming quarters.

It's a historic time to be participating in this rapidly growing industry as CBD pushes into global mainstream channels. EXL has engaged the services of a US distribution partner to drive sales of Elixinol branded products, starting with one major success of a leading US national retailer. To assist with the Company's growth, we are excited to have the expertise of Greg Ellery join the EXL Board and expansion of our global executive team with Stratos stepping down from the Board to become Chief Commercial and Legal Officer. ”

Strategic outlook: delivering on our corporate strategy

Capturing substantial global growth opportunity in hemp-CBD and medical cannabis



A decorative graphic on the left side of the slide features several overlapping white, stylized leaves or petals. These elements are set against a solid blue horizontal band that spans the width of the slide. The leaves have soft shadows, giving them a three-dimensional appearance.

Appendix

www.elixinolglobal.com

Reconciliation to FY2018 underlying EBITDA and NPAT

(\$m)	FY2018
Statutory NPAT	(0.9)
Tax expense	0.4
Depreciation & amortization	0.8
Interest income/finance costs	(0.4)
Statutory EBITDA	(0.1)
<i>Share based payment expense</i>	0.8
Underlying EBITDA	0.7
Statutory NPAT	(0.9)
Share based payment expense (after tax)	0.6
Amortization acquired intangibles (after tax)	0.3
Tax benefit of losses	0.7
Underlying NPAT	0.7

* FY2017 is shown on a pro forma basis. EXL reports in A\$ million and on a 31 December year end.

| For more information:

Investor relations and media please contact:

Australia

Glen Zurcher

Account Director, IR Department

IR@elixinolglobal.com | +61 420 249 299

United States of America

Cody Slach

Managing Director, Gateway Investor Relations

USIR@elixinolglobal.com | +1 949 574 3860



www.elixinolglobal.com